Global Immuno Oncology Assays Market Size By Product (Consumables, Software and Services), By Technology (Polymerase Chain Reaction (PCR), Flow Cytometry), By Indication (Lung Cancer, Breast Cancer), By Application (Research Applications, Clinical Diagnostics), By Geographic Scope and Forecast

Immuno Oncology Assays Market Size And Forecast

Immuno Oncology Assays Market size was valued at USD 3.29 Billion in 2021 and is projected to reach USD 5.05 Billion by 2030, growing at a CAGR of 5.70% from 2023 to 2030.

In the upcoming years, the market for immuno-oncology assays is anticipated to maintain its upward trend due to factors such as the rising incidence of cancer, the rising demand for personalised medicine, rising investments in research and development activities, technological advancements in immuno-oncology assays, and rising government funding and initiatives. The Global Immuno Oncology Assays Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Immuno Oncology Assays Market Definition

Since foreign bacteria and viruses have the potential to create a disease or infection over time, the immune system of the human body is in charge of removing them from the body once they enter. The body’s immune system eliminates foreign objects, including cancer cells, from the body. Scientists are utilising technology to create immuno-oncology in their quest to create a cancer treatment that works. Using the body’s natural defences against the cancer-causing cells in an effort to eradicate them, immuno oncology is a technology. Because to its specificity, versatility, and durability, immuno oncology has become more popular as a cancer treatment over the past few years. Immuno Oncology’s objective is to supervise the interactions which take place between the cancer-causing cells and the immune system of the body.

Immuno-oncology assays can be carried out in a variety of ways utilising a variety of sample types, including blood, DNA/RNA, and tumours. The various approaches could include looking at the cellular component in the blood or utilising immunoassays to measure the proteins circulating in it. An other technique to examine the tumour cells is flow cytometry. There are many different types of immuno-oncology tests, including immuno-oncology tests using tumour cells, immuno-oncology tests using T cells, immuno-oncology tests using natural killer cells, immuno-oncology tests using macrophages, immuno-oncology tests using dendritic cells, and immuno-oncology tests using neutrophils.

The benefits of flow cytometry are numerous. It enables the detection of cellular markers using intracellular or surface staining methods. These markers may distinguish between various cell types, which is helpful in the creation of cell-specific treatments. NK cells, innate lymphoid cells, and macrophages can all express CD4, which is a common marker for T cell subsets and involved in T cell activation. It is also simple to integrate flow cytometry into immuno-oncology due to the many advantages it offers, such as the capacity to describe, count, and organise fluorescently labelled cells based on fluorescence emission. Understanding is improved by the capacity to measure and describe particular subsets of cell populations, such as circulating T cells.

Global Immuno Oncology Assays Market Overview

The increase in cancer incidences is a significant driving factor for the market for immuno oncology assays. In 2020, there will be 19.3 million new instances of cancer and 10 million cancer-related deaths, according to data from the updated Globocan 2020 that was published by the IARC on December 14th. More than 50 million people, according to these new figures, are still alive five years after receiving a cancer diagnosis. Cancer is a form of illness that progresses through numerous molecular mechanisms and has several stages. Because of this, finding a universal cancer treatment is challenging.

So, it is crucial to comprehend how the immune system and these cancer cells interact in order to create various cancer therapies. The market has expanded as a result of technological developments in immuno oncology assays. The immune system interacts with many different types of cells in a very complicated way, rather than just one type of cell. As a result, single-cell technologies have become effective resources for learning about the tumour microenvironment (TME).

Other immune cells of the innate and adaptive immune systems, including as DCs, macrophages, NK cells, and B cells, have also been demonstrated to contribute to tumour growth and immunotherapy responses, despite the fact that much work has been put into characterizing T-cells. The market is constrained, nonetheless, by the high failure rate of pharmacological studies and the significant sums invested in the discovery and development of numerous medications. Also, the market’s growth is facilitated by the rising cancer prevalence in developing nations. In 2020, China was responsible for 24% of all newly diagnosed cases and 30% of all cancer-related fatalities worldwide. Growing healthcare costs present prospects for business expansion as well.

Market Attractiveness

The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Immuno Oncology Assays Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.

Porter’s Five Forces

The image provided would further help to get information about Porter’s five forces framework providing a blueprint for understanding the behavior of competitors and a player’s strategic positioning in the respective industry. The porter’s five forces model can be used to assess the competitive landscape in global Immuno Oncology Assays Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

Global Immuno Oncology Assays Market Segmentation Analysis

The Global Immuno Oncology Assays Market is segmented on the basis of Product, Application, Indication, Technology, and Geography.

Immuno Oncology Assays Market, By Product

• Consumables
• Software and Services
• Instruments

Based on Product, the market is segmented into Consumables, Software and Services, and Instruments. The immuno oncology assays market’s major component is the consumables sector. The supplies used in immuno-oncology assays for sample preparation, processing, and data interpretation are known as consumables. The main factor boosting the development of this market is the rising use of consumables in research and diagnostic applications. Products including antibodies, test kits, reagents, and other lab supplies are included in the consumables section. Due to the increased need for immuno-oncology assays, these products are already widely employed in research and diagnostic applications.

Also, the market’s continued dominance in the consumables sector is anticipated as a result of the growing usage of personalised medicine and the development of novel cancer immunotherapies, both of which call for the use of immuno-oncology assays for patient selection and monitoring.

Immuno Oncology Assays Market, By Application

• Research Applications
• Clinical Diagnostics

Based on Application, the market is segmented into Research Applications and Clinical Diagnostics. The market for immuno-oncology assays continues to be dominated by research applications, and in the upcoming years, demand for these assays is anticipated to increase. Further investigation into the immune system’s reaction to cancer cells will be necessary when novel cancer immunotherapies are created, which will increase the demand for immuno-oncology assays in research applications. In order to better understand how the immune system reacts to cancer cells and to create new cancer immunotherapies, immuno-oncology tests are widely employed in research. Basic research, drug discovery, and the preclinical testing of cancer immunotherapies are examples of research applications.

Immuno Oncology Assays Market, By Indication

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Bladder Cancer
• Melanoma
• Other Cancers

Based on Indication, the market is segmented into Lung Cancer, Breast Cancer, Colorectal Cancer, Bladder Cancer, Melanoma, and Other Cancers. Cancers on the basis of indication. The main component of this market is the lung cancer category. It is brought on by the increase in lung cancer cases worldwide. WHO estimates that 2.21 million people will have lung cancer in 2020.

Immuno Oncology Assays Market, By Technology

• Polymerase Chain Reaction (PCR)
• Flow Cytometry
• Immunoassay
• Next-Generation Sequencing (NGS)
• In Situ Hybridization (ISH)

Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Flow Cytometry, Immunoassay, Next-Generation Sequencing (NGS), and In Situ Hybridization (ISH). While PCR is an important technology used in immuno oncology assays, it may not necessarily be the major constituting segment of the market. The market for immuno oncology assays is primarily driven by the increasing prevalence of cancer, growing demand for personalized medicine, and rising investments in research and development activities. The consumables segment, which includes assays kits, reagents, and antibodies, is the largest constituent in the market, while the clinical diagnostics segment is the dominant application segment.

Immuno Oncology Assays Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

On the basis of Geography, the Global Immuno Oncology Assays Market is classified into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. North America is one of the largest and most mature markets for immuno-oncology assays, but it may not necessarily be the highest constituent of the market. The North American market is driven by a number of reasons, including the existence of a significant percentage of biopharmaceutical businesses, improved medical infrastructure, and supportive government initiatives. However, the market for immuno-oncology assays is expected to grow in all regions, including emerging markets such as Latin America, Middle East & Africa, and Asia Pacific. This is brought on by the rising cancer rate, rising healthcare costs, and expanding knowledge of immunotherapy’s advantages.

Key Players

The “Global Immuno Oncology Assays Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Agilent Technologies, Inc., PerkinElmer, Inc., Illumina, Inc., Thermo Fisher Scientific, Inc., Crown Bioscience Inc., Merck & Company, Inc., InSphero Inc., F.Hoffmann-La Roche Ltd., HTG Molecular Diagnostics, Inc., among others.

The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In January 2022, Illumina announced that it had acquired GRAIL, a company focused on developing a blood test for early cancer detection. The acquisition is expected to strengthen Illumina’s position in the oncology market and accelerate the development of non-invasive cancer screening tests.
• In October 2021, Qiagen announced the launch of its QIAseq Pan-Cancer Immune Profiling Panel, which is a targeted NGS panel designed to identify immune-related genetic alterations in tumor samples. The panel is designed to help researchers and clinicians better understand the tumor microenvironment and develop more effective immunotherapies.
• In August 2021, the US Food and Drug Administration approved Keytruda (pembrolizumab), a drug manufactured by Merck, for use in combination with chemotherapy to treat a number of advanced or metastatic esophageal and gastroesophageal junction cancers. The checkpoint inhibitor Keytruda prevents the immune system from recognising and eliminating cancer cells by blocking a protein known as PD-1.

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovati